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ABSTRACT 
Nowadays, developements in nanotechnology have leeds an increased application of this newborn 
technology in cancer treatment. In this study, a stabilized micelle was developed to load HpD in order to be 
used in photodynamic treatment of cancer in an animal model. To construct micelles, Pluronic P-105 was 
used and stabilized to encapsulate HpD. This process includes a 24 h polymerization in which the first 3.5 h 
was in the presence of N2 purge and was continued at 65°C. In this reaction, NNDEA and benzoil peroxide 
(BP) were used for stabilization of micelles and initiation of reaction, respectively. DLS analysis of micelles 
revealed that the size of them before and after drug encapsulation was 14 nm and 23.5 nm, respectively. To 
assess drug loading, drug standard curve was obtained and its loading was obtained as 2 mg/ml. To extract 
free drug from complex, it was dialyzed against water and its stability profile was measured up to one month 
which was more than 80%. According to obtained results, this complex could be used to reduce side effects 
in photodynamic therapy. Besides, according to tumor characteristics and physical properties of micelles, it 
is possible to enhance drug release and uptake at tumor site. 
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INTRODUCTION 
Application of nanotechnology and 
nanoparticles in medicine is continuously being 
improved especially in cancer diagnosis and 
treatment [1-6]. Although significant advances in 
the definition of cancer, the problem of targeting 
cancer cells still exists. Nanotechnology has the 
capability to target cancer cells and reduce side 
effects to normal tissues [7-9]. Among several 
modalities in treatment of cancer, one with 
targeting potential is photodynamic therapy in 
which it is possible to enhance treatment 
efficiency using nanotechnology [10]. In this 
method, a photosensitizer drug is injected 
systemically or locally to patient and due to drug 
biokinetics and tumor physiology, drug is 
accumulated in tumor tissue and then tumor tissue 
is exposed to laser light which leads to production 
of cytotoxic agents and destruction of tumor 
tissue [11, 12] which is being used in a wide 
range of cancers [11, 13, 14]. The main problem 
in this method, is hydrophobicity of 
photosensitizer drugs which after injection and 
before reaching tumor tissue, disassemble and 
exits body via several pathways [12, 15, 16]; this 
causes a reducion in drug uptake by tumor and 
reduced treatment efficiency.  
To overcome this problem and increase drug 
retention in vivo, one way is to use nanocarriers 
such as liposomes, micelles and polymeric 
nanoparticles [6, 17-22] which depend on drug 
type and its chemical properties [1, 2, 5, 23-26].  
In this work, due to wide range of HpD 
applications in photodynamic therapy, HpD  
loaded nanomicelles were synthesized and their 
size and stability were assessed. This complex has 
the merit of its hydrophobic-hydrophilic structure 
which enables an enhanced circulation time [16, 
18, 27, 28] and has the capability to be used in 
treatment of a wide range of cancers.  
 
MATERIALS AND METHODS 
Chemicals 
Hematoporphyrin (HpD) was obtained from 
Merck (Merck KGaA, Darmstadt, Germany). 
Pluronic P-105 was provided by the BASF Corp. 
 




(Mount Olive, NJ, USA). N-NDiethylacrylamide 




(BAC) was obtained from Fluka (Sigma–Aldrich, 
UK), and benzoyl peroxide (BP) was obtained 
from Merck (Merck KGaA, Darmstadt, 
Germany). 
Methods 
Polymeric micelles were prepared using Pluronic 
P-105, which is a triblock copolymer consisting 
of blocks of poly propylene oxide (PPO) and poly 
ethylene oxide (PEO) in the form PEO37–PPO56–
PEO37. A solution of NaCl and 10 wt.% Pluronic 
P-105 in distilled water was added to a round-
bottom balloon, which was stirred for 20 min 
while immersed in a water bath under a nitrogen 
purge at a temperature of 65°C. A mixture of 
BAC, BP and NNDEA (26:1:55 weight ratio) was 
added to above solution and it was allowed to stir 
at this temperature under a nitrogen purge for 3.5 
h. After turning off nitrogen flow, the mixture 
was allowed to polymerize for 19.5 h. The size 
distribution of the micelles was measured by 
dynamic light scattering (DLS) (Malvern 
Instruments Ltd., Malvern, UK). 
To load HpD into nanomicelles, diluted solution 
of drug in distilled water was mixed with solution 
of stabilized nanomicelles and stirred gently to 
form a uniform solution. The resultant solution 
was dialyzed against water for 3 h (5 kDa cut off) 
to extract free drug from encapsulated drug 
solution. Finally, using flourimetry (Jasco FP-
6200, Tokyo, Japan), a standard curve for 
encapsulated drug was ploted; to do so, excitation 
and emission wavelength were set at 320 nm and 
480 nm respectively and by adding known 
amounts of drug to micellar solution, this standard 
curve was obtained; so it is possible to measure 
drug loading in nanomicelles (29). Size 
measurements of complex were similar to size 
measurements of nanomicelles. Finally, stability 
profile of complex was obtained for 30 d at 4 °C.  
 
RESULTS 
      Figure 1 shows DLS results of nanomicelles. 
As it is observed, the mean diameter of 
nanomicelles is 14 nm. In this graph, vertical axis 
shows the intensity of scattered laser light and the 
horizontal axis shows size of nanomicelles and 
light intensity at each size is a measure of number 
of particles in that size. Figure 2, shows the 
fluorescence spectrum of HpD; to obtain this 
spectrum, flourimetric measurements were done 
from 300 nm to 600 nm which covers drug 
excitation wavelength (320 nm) and drug 



























Figure 1. DLS results of micelles without drug in 


















Figure 2. Fluorescent spectrum of 
Hematoporphyrin with its excitation and emission 
peaks.  
 
According to these flourimetric characteristics of 
HpD, it is possible to draw a drug standard curve 
in nanomicelles as figure 3 and measure drug 
loading. In this graph, horizontal axis shows the 
amount of fluorescent emission of sample and 
vertical axis shows micellar drug concentration in 
mg/ml and linear regression equation of these data 
is presented on this graph. Using this standard 
curve, each time after complex synthesis, it is 
possible to find out drug concentration in 
nanomicelles from its fluorescent emission. As it 
is shown in this figure, maximum loading of drug 
in micelle is 2 mg/ml. 
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Figure 3. Standard curve for drug loading into 


























Figure 4. DLS results of complex in which mean 
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Figure 5. Stability profile of complex normalized 







After measurement of micellar drug loading, their 
size distribution was determined using DLS 
which results are presented in figure 4 and mean 
diameter of complex was obtained as 23.5 
nm.Another important characteristic of complex is 
its stability versus time; to do so, fluorescent 
emission of drug was measured at different times 
from its synthesis up to one month at 4 °C and the 
amount of fluorescent emission was normalized to 
first day. Because drug release from complex 
leads to a decrease in fluorescent emission at the 
above mentioned emission wavelength, it is 
possible to use this parameter as a measure of 
complex stability which is shown in figure 5. In 
this figure, the percentage complex stability is 
shown on vertical axis and measurement time is 
presented on horizontal axis up to one month. As 
it is obvious from this graph, complex stability 
reaches a level of 80% after one month. 
 
DISCUSSION 
      A polymeric drug carrier for HpD to be used 
in photodynamic therapy was presented. One of 
the merits of this family of polymeric drug 
carriers is their hydrophilic-hydrophobic structure 
which enables one to enhance delivery of 
hydrophobic drugs; besides their PEO-PPO-PEO 
structure, forms a self-assemble platform that 
collapses by sonication and releases their drug 
loading and makes them good candidates for 
treatment of a wide range of cancers [11-13, 30].  
 
CONCLUSION 
      The presented HpD complex has the 
possibility of using in photodynamic therapy of 
several tumors such as GI tumors in experimental 
animal models. Besides, it is possible to use this 
complex in targeted therapy in which local 
sonication causes drug release in deeply sited 
tumors without any worry about side effects 
similar to ionizing radiation. Because of tumor 
vasculature, drug is accumulated in tumor 
passively and local sonication of tumor causes an 
enhanced drug uptake due to sonoporation. 
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